Status
Completed
Phase
Not applicable
Enrollment
40
Locations
1
Results
Not posted
Publications
0
Study summary
The aim of this study was to compare the clinical outcomes in progesterone primed endometrial protocol versus gonadotropin-releasing hormone antagonist protocol in women undergoing assisted reproductive treatments.
Utilizing the assisted reproductive techniques (ART) has exhibited a substantial rise within the last years, emerging as a crucial modern medicine component with reliable results. The utilized protocols for endometrial preparation in ART are aimed at maximizing the treatments' success. Typically, utilizing gonadotropin-stimulating hormone (GnRH) antagonists or agonists remains involved for preventing an early luteinizing hormone (LH) peak along ovulation prior to oocytes retrieval. The GnRH-antagonist (GnRH-a) protocol is favored by many clinicians as well as patients due to its simplicity, convenience, flexibility, and absence of functional ovarian cysts or "menopausal" symptoms linked to the agonist protocol. Nevertheless, some RCTs' findings address that the antagonist protocol yields a reduced oocytes' number. Additionally, it exhibits lower pregnancy rates as opposed to the agonist extended therapy.
Interventions
OTHER
The cases were received soft progesterone capsules (brand name: Utrogestan, 100 mg, Laboratories Besins International, France) 100 mg and 150 IU of human menopausal gonadotropin (hMG) concomitantly from the menstrual cycle (MC) day 3 until the trigger day.
OTHER
The cases were received the gonadotropin-releasing hormone antagonist (GnRH-ant) protocol consisting of HMG 150 IU's daily injection from MC 3 until the trigger day. GnRH-ant (Cetrotide, 0.25 mg, MerckSerono) was started when at least one of the following criteria were met: LH \>10 IU/L, the presence of at least one follicle with mean diameter \>14 mm, or serum E2 level \>600 pg/mL.
Timeline
First posted
Mar 7, 2024
Study start
Sep 1, 2022
Primary completion
Jan 1, 2024
Study completion
Jan 1, 2024
Results posted
Not reported
Registry updated
Mar 7, 2024
Outcomes
The number of retrieved oocytes
Time frame · 34 to 36 hours post HCG administration
Retrieved oocytes will be collected after ovarian induction by gonadotropin injection
Pregnancy rate
Time frame · Fourteen days following the transfer
Biochemical pregnancy was determined as serum HCG higher than 25 mIU/ml at twelve to fourteen days following the transfer. Gynecological ultrasound assessment was accomplished at thirty to thirty-five following the transfer. Additionally, the gestational sac existence was regarded as clinical pregnancy, with the clinical pregnancy rate = (clinical pregnancy cycles' number/ all transfer cycles' number) × 100%. Moreover, live birth rate equals (live birth cycles' number/ all transfer cycles' number) × 100%
Eligibility
Inclusion Criteria: * Age 21 to 40 years. * A basal antral follicle count (AFC) \<6. * All patients had to have a body mass index between 18.5 to 29.9 kg/m2. * Undergoing IVF/ICSI cycles. * With previous poor response to conventional prolonged therapy utilizing GnRH agonists (retrieving three oocytes). Exclusion Criteria: * Cycles with fresh embryo transfer. * Transfers of cleavage embryos (d2/d3). * Embryos from cycles with preimplantation genetic screening. * Cryopreservation of oocytes. * Oocyte donation cycles. * Cycles that produced embryos but without et at the time of the analysis.
Study locations
Egypt. Showing up to 24 locations stored in the fast local snapshot.
New Valley University
New Valley, New Valley Governorate, Egypt
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Ahmed Saad · Poor Ovarian Reserve · Infertility (IVF Patients)
Phase 1 / Phase 2
Not yet recruiting
100
2026-07
Centro A.M.B.R.A. (Associazione Medici e Biologi per la Riproduzione Assistita) · Infertility, Female · Ovulation Induction
Early Phase 1
Not yet recruiting
189
2026-07
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany · Infertility
Phase 3
Recruiting
266
2026-07
ART Fertility Clinics LLC · Ovarian Stimulation
Not applicable
Recruiting
150
2026-06
Bedaya Hospital · Infertility
Phase 2
Recruiting
120
2026-05
Beni-Suef University · IVF · PCO
Phase 2 / Phase 3
Completed
200
2026-04
Assistance Publique - Hôpitaux de Paris · Infertility
Phase 4
Completed
129
2026-04
Institut Cancerologie de l'Ouest · Breast Cancer
Phase 2
Active, not recruiting
102
2026-03
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.